Yet, does the principle that the presence of especially synchronous liver metastasis in resectable PDAC denies a curative resection deprive patients of a possible benefit from a simultaneous resection? 
| INTRODUC TI ON
Pancreatic ductal adenocarcinoma (PDAC) is one of the most deadly cancers among gastrointestinal tumors. Incidence and tumor-dependent deaths increase year by year. 1 Because of the tumor's invasiveness and rapid development of lymph node and distant metastases, 5-year overall survival is poor, yet in patients with resectable PDAC, negative resection margins, and no evidence of lymph node metastases, overall 5-year survival can reach 36 months. 2 Although in other types of cancer, progress in therapy and lifetime prolongation for the patient are being made, striking improvements in the therapy of pancreatic cancer are sparse. 3, 4 At time of diagnosis, most patients already harbor distant metastases resulting in only 10%-20% of patients being in a curable stage depending on the classification of actual guidelines. The gold standard for patients in stage IV is systemic chemotherapy with FOLFIRINOX or gemcitabine with palliative intent. 5 In 1995, Hellman and Weichselbaum first proposed the clinically significant condition of oligometastasis, which is a state between local and systemic disease, and advocated the potential of curatively intended local treatment. 6 In contrast to many other cancers, resection of hepatic oligometastasis in patients with PDAC is still a controversial issue. Whereas liver and lung metastases are no contraindication for even sequential resections in patients with metastatic colorectal cancer, most surgeons would not carry out any type of resection of distant metastases in PDAC. 2, 7 This is mainly based on the high morbidity and mortality of pancreatic resections, the short survival of stage IV patients, and the lack of any randomized controlled trials (RCT). Furthermore, national and international guidelines do not recommend resection in cases of distant metastases. 8, 9 Yet, does the principle that the presence of especially synchronous liver metastasis in resectable PDAC denies a curative resection deprive patients of a possible benefit from a simultaneous resection? we undertook a review of the current literature related to the role of potential curative surgery for hepatic metastasis in PDAC.
| HEPATI C ME TA S TA S E S IN PDAC
Because of the venous drain of the upper gastrointestinal organs via the portal vein, liver metastases are very common and the liver is the most affected organ for distant metastases in PDAC, followed by peritoneum, and lung. 11, 12 In most stage IV patients, at the time of Oligometastases means less than five metastases in one organ. 2 As a result of better preoperative imaging, metastases are detected earlier and at smaller size. The probability of detecting lymph node and distant metastases becomes higher, because of better resolution in computed tomography (CT) scans. However, this determines whether or not the patient is in a curable, resectable stage, depending on actual guidelines. 8, 9 Nevertheless, up to 12% of patients present liver metastases or peritoneal metastases in the explorative laparotomy, being occult in the preoperative staging. 13 These metastases might be too small to be seen in CT scans or masked because of distinct cholestasis. Cases of young patients with resectable primary and metastases are particular subjects of current discussions.
| CHEMOTHER APY FOR LIVER ME TA S TA S E S IN PDAC
In 2011, Conroy et al 14 conducted a study and randomly assigned 342 patients with metastatic PDAC and an Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1 to receive FOLFIRINOX or gemcitabine. Six months of chemotherapy were recommended in both groups. The authors reported a median overall survival of 11.1 months in the FOLFIRINOX group as compared with 6.8 months in the gemcitabine group (P < 0.001). Median progression-free survival was 6.4 months in the FOLFIRINOX group and 3.3 months in the gemcitabine group (P < 0.001). The objective response rate was 31.6% in the FOLFIRINOX group versus 9.4% in the gemcitabine group (P < 0.001). The authors concluded that, compared with gemcitabine, FOLFIRINOX is associated with a survival advantage yet had increased toxicity. After that study, FOLFIRINOX became the gold standard for first-line treatment of patients with stage IV PDAC. Therefore, all curatively intended surgical procedures, which are now being debated, should achieve a higher median survival rate of at least 11 months.
| SURG ERY FOR LIVER ME TA S TA S E S IN PDAC
Surgical resection of liver metastases in colorectal cancer and for neuroendocrine tumors has shown 5-year survival rates as high as 40%-71% and 61%-76%, respectively. 5 So why is it still such an emotional debate as to whether hepatic oligometastases be resected even when it is technically achievable?
First, although pancreatic surgery became safer as perioperative morbidity and mortality decreased, it is still a challenging field of surgery. Very recently, Nimptsch and colleagues aimed to determine the unbiased mortality rate for pancreatic surgery in Germany. 15 They analyzed the data of 58 000 patients and found a mortality rate that ranged from 7.3% to 22.9%, depending on the procedure (distal vs total pancreatectomy) and on the number of cases carried out by the clinic. Carried out in high-volume centers, mortality rates lie under 5%. 16 Of course, synchronous hepatic resections increase morbidity and mortality, making it a high-risk procedure, although some reports have shown no significant increase in perioperative morbidity or mortality after pancreatectomy with synchronous hepatic metastasectomy. 17, 18 Clearly, these operations should only be done in high-volume centers.
Second, as already mentioned, national and international guidelines do not recommend resection in cases of distant metastases in PDAC, 8, 9 neither if these appear during the preoperative staging, nor intraoperatively, even if they are technically resectable and even if a R0 situation can be achieved; this is mainly due to the following viewpoint.
There is no evidence from any RCT that synchronous or metachronous resection of liver metastasis in PDAC prolongs survival.
Most data are derived from retrospective single-center studies, lacking any RCT until now ( Table 1 ).
The largest study so far by Hackert et al 19 Sixty-eight percent of the patients experienced any type of morbidity, including a minor wound infection as well as severe morbidities.
One patient died. 20 An Italian study by Crippa et al 21 was 27 months. It is worth mentioning that the 24 patients with a good response to chemotherapy constituted only 4.5% of the 535 patients that were observed in the study.
Interestingly, there are several studies which indicate that longer survival is associated with metachronous resection of liver metastases instead of synchronous disease. 23, 24, 26 Zanini et al 23 reported an OS of 11.4 months after metachronous resection versus 8.3 months after synchronous resection. The authors included only 15 patients over a period of 11 years, so it is not possible to draw any conclusions from such a small cohort.
Another trial found an OS of 31 months after metachronous resection versus 8 months after synchronous resection.
The OS of the synchronously resected group was even lower than the OS of the chemotherapy group that had no surgery (11 months). 24 The fact of having synchronous or metachronous liver metastases alone might have an effect on survival and serve a prognostic value. Synchronous metastases could be interpreted as a more advanced stage of disease compared to patients with the first evidence of liver metastases in follow ups after initial treatment.
In a recent review, Lee et al 5 identified a total of 10 studies with 281 patients, some of them already discussed above. For patients with synchronous liver metastases, the most common type of pancreatic resection was pancreatoduodenectomy (n = 125) followed by distal pancreatic resection (n = 75) and total pancreatectomy (n = 27). The most common type of liver resection performed were atypical resections (n = 61), wedge resections (n = 32) and segmentectomies (n = 25), with hepatectomies (n = 5) being least common.
Synchronous liver resection had higher morbidity than metachronous liver resection (33%-45% vs 0%-21%). The 30-day post-operative mortality ranged from 0% to 9.1%.
Six studies showed a positive effect on survival after surgery, whereas four did not. Sixty percent of patients had disease recurrence in the liver after curative resection. Median overall survival ranged from 6 to 39 months. Overall survival was significantly better for patients who had a good response to neoadjuvant chemotherapy and underwent metachronous liver resection.
These studies are difficult to compare, as there is mixed information about the recruitment of patients, their general condition, their comorbidities, or their quality of life. Furthermore, the perioperative multimodal concept differs between neoadjuvant versus adjuvant or both, as well as the choice of chemotherapeutics.
| WHAT S HOULD B E THE CRITERIA FOR HEPATI C ME TA S TA S E S RE S EC TI ON? WHI CH PATIENTS S HOULD B E S ELEC TED FOR SURG ERY ?
As mentioned earlier, the proper selection of surgical candidate patients seems to be crucial. The presented studies, heterogeneous as they are, underline this challenge. So far, there are no clear cut-off levels in tumor marker, no biomarker, or number and size of liver metastases that can be defined. We know that the most important result for long-term survival is achievement of R0 resection. 
| CON CLUS IONS
Surgery for liver metastases in stage IV PDAC patients can be done safely. Adding hepatic resection to pancreatectomy often does not lead to higher mortalities than pancreatic resection alone. Although in some reports mortality rate is up to 9.1%, most of the high-volume centers describe a much lower mortality, minimizing the risk for the patient. 
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